Clinical Trial Update: Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma. [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/3 clinical trial evaluating EIK1001 in combination with pembrolizumab versus placebo with pembrolizumab as first-line therapy in adults with advanced …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• EIK1001 (EIK1001)
• KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: Eikon Therapeutics | Conditions: Advanced Melanoma | Phase 2, Phase 3 | Status: RECRUITING